Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
14
TRIB Quote, Financials, Valuation and Earnings
Last price:
$0.80
Seasonality move
:
12.35%
Day range:
$0.75 - $0.84
52-week range:
$0.75 - $3.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.15x
P/B ratio:
--
Volume:
45.6K
Avg. volume:
139.4K
1-year change:
-68%
Market cap:
$22M
Revenue:
$56.8M
EPS (TTM):
-$2.28
Analysts' Opinion
-
Consensus RatingTrinity Biotech PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Trinity Biotech PLC has an estimated upside of 1775% from its current price of $0.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.80.
Fair Value
-
According to the consensus of 0 analysts, Trinity Biotech PLC has 1775% upside to fair value with a price target of -- per share.
TRIB vs. S&P 500
-
Over the past 5 trading days, Trinity Biotech PLC has underperformed the S&P 500 by -9.81% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Trinity Biotech PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Trinity Biotech PLC has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Trinity Biotech PLC reported revenues of $15.2M.
Earnings Growth
-
Trinity Biotech PLC earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Trinity Biotech PLC reported earnings per share of -$0.46.
Enterprise value:
101M
EV / Invested capital:
1.82x
Price / LTM sales:
0.15x
EV / EBIT:
--
EV / Revenue:
1.71x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.51x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$21.1M
Return On Assets:
-25.1%
Net Income Margin (TTM):
-34.39%
Return On Equity:
--
Return On Invested Capital:
-45.03%
Operating Margin:
-14.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $54.5M | $59.1M | $59.1M | $14.7M | $15.2M | |
| Gross Profit | $14.5M | $20.3M | $21.1M | $4.3M | $5.3M | |
| Operating Income | -$14.1M | -$17.6M | -$10.4M | -$4.5M | -$2.2M | |
| EBITDA | -$12.4M | -$42.1M | -$8.4M | -$3.9M | -$1.1M | |
| Diluted EPS | -$5.40 | -$3.75 | -$2.28 | -$0.88 | -$0.46 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $72.4M | $78.2M | $49.8M | $43.8M | $46.1M | |
| Total Assets | $136.1M | $122.8M | $97.9M | $63.6M | $97.4M | |
| Current Liabilities | $23.1M | $102.9M | $14.7M | $12.7M | $28.1M | |
| Total Liabilities | $129M | $122M | $91.3M | $81.1M | $123.8M | |
| Total Equity | $7.1M | $810K | $6.6M | -$17.5M | -$26.3M | |
| Total Debt | $83.1M | $83.2M | $57.9M | $54.5M | $81.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.6M | -$10M | -$7.3M | -$4.7M | -$3.6M | |
| Cash From Investing | -$7.3M | $24.5M | -$21.1M | -$886K | -$3.1M | |
| Cash From Financing | -$14.5M | -$15.7M | $25.2M | -$2.4M | $4.2M | |
| Free Cash Flow | -$5.7M | -$12.9M | -$15.5M | -$5.3M | -$6.3M | |
TRIB
Sector
Market Cap
$22M
$44.6M
Price % of 52-Week High
22.54%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-68%
-29.09%
Beta (5-Year)
0.969
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.85
200-day SMA
Sell
Level
$1.90
Bollinger Bands (100)
Sell
Level
1.09 - 2.17
Chaikin Money Flow
Sell
Level
-102.5M
20-day SMA
Sell
Level
$0.97
Relative Strength Index (RSI14)
Sell
Level
27.64
ADX Line
Sell
Level
20.58
Williams %R
Buy
Level
-88.345
50-day SMA
Sell
Level
$1.39
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
151.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.0735)
Sell
CA Score
(Annual)
Level (-4.8512)
Buy
Beneish M-Score
(Annual)
Level (-5.064)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (8.6096)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Stock Forecast FAQ
In the current month, TRIB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRIB average analyst price target in the past 3 months is --.
-
Where Will Trinity Biotech PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Trinity Biotech PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Trinity Biotech PLC?
Analysts are divided on their view about Trinity Biotech PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Trinity Biotech PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is Trinity Biotech PLC's Price Target?
The price target for Trinity Biotech PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRIB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Trinity Biotech PLC is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TRIB?
You can purchase shares of Trinity Biotech PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Trinity Biotech PLC shares.
-
What Is The Trinity Biotech PLC Share Price Today?
Trinity Biotech PLC was last trading at $0.80 per share. This represents the most recent stock quote for Trinity Biotech PLC. Yesterday, Trinity Biotech PLC closed at $0.80 per share.
-
How To Buy Trinity Biotech PLC Stock Online?
In order to purchase Trinity Biotech PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
